Heart failure & cardiomyopathiesSecondary analysis
Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy
- Secondary analysis of the REVIVED-BCIS2 randomised trial
- independent core laboratories
Authors' conclusion
In patients with severe LV dysfunction, neither complete anatomical nor viability-guided revascularization was associated with improved event-free survival compared with incomplete revascularization or treatment with medical therapy alone.
Study context
- Population
- Patients with severe left ventricular (LV) dysfunction (ischemic cardiomyopathy) in REVIVED-BCIS2 with angiograms and viability studies availableof 700 randomized
- Participants
- 670 patients
- Comparison
- Complete anatomical or viability-guided revascularization (percutaneous coronary intervention (PCI)) vs optimal medical therapy alone
- Primary endpoint
- Death or hospitalization for HF
Primary result
As reported in the abstract
Each group vs optimal medical therapy aloneHazard ratio (95% CI)
Complete anatomical revascularization
0.90(0.62–1.32)
Complete viability-guided revascularization
0.95(0.66–1.35)
Further findings
Median completeness of revascularization (PCI)
- Median RIcoro
- 67%
- Median RImyo
- 85%
Sensitivity analysis by residual SYNTAX score
- No association with outcome
Original publication
Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. J Am Coll Cardiol. Published 15 May 2024. doi:10.1016/j.jacc.2024.04.043
Summarised from the published abstract; every number is checked against it